Corrections Log: What We Got Wrong, and When We Fixed It
Written by Transparent Peptide research desk·Published 2026-08-04·Last reviewed 2026-08-04·Methodology
This page is maintained. Prices are re-read at source and dated; evidence is checked against the published trial. Newest across the site: news · research · corrections.
A publication that never corrects itself is not more accurate than one that does — it is less observable. Every correction is listed in full, with what we said, what is correct and why it mattered.
Corrections are published at the same prominence as the original claim, and affected pages carry the correction inline rather than being edited silently.
· COR-001 · Material — editorial governance
Every page carrying a medical reviewer byline
What we said: We named a physician medical reviewer in the byline of 112 pages and in the reviewedBy property of 24 structured-data blocks.
What is correct: That reviewer credit has been withdrawn from every page, from the structured data, from the editorial board page and from the medical review policy. Pages that previously carried it now show the researcher and the review dates without a named physician reviewer.
Why it mattered: A medical reviewer credit is a claim about who checked the clinical content. Withdrawing it from the visible byline while leaving it in the structured data would retract the claim to readers and keep asserting it to machines. Both were removed together, and the change is published here rather than made silently.
What we said: Trial figures appeared near compounded products without a consistent statement of which product the trial studied.
What is correct: Every efficacy figure on this site was collected on an FDA-approved product. No compounded preparation has a trial of its own, and no figure transfers to one.
Why it mattered: A number placed beside a product implies it describes that product.
· COR-003 · Material — starter price quoted as the price of treatment
Pages quoting the approved oral semaglutide price
What we said: The approved oral semaglutide tablet was described at $149 a month without stating which doses that covers.
What is correct: The manufacturer's own price guide sets $149 for the 1.5 mg and 4 mg doses and $299 for the 9 mg and 25 mg maintenance doses. The $149 rate on 4 mg ends 31 August 2026, after which it becomes $199.
Why it mattered: Quoting a starter-dose figure as the price of treatment is the error this publication documents in provider marketing.
How to report an error
Email the research desk with the page and the figure you believe is wrong. We would rather a figure be found and corrected than repeated.